SUMMARY Nitrates have been shown to decrease portal pressure in cirrhotic patients with portal hypertension and this has been attributed to decreased portal venous resistance. We studied the effect and mechanism of action of oral administration of isosorbide-5-mononitrate (Is-5-Mn) (20 mg), which, unlike the dinitrate, does not require hepatic biotransformation to a vasoactive metabolite on portal and systemic haemodynamics in 11 patients with portal hypertension complicating cirrhosis. A significant reduction in portal pressure gradient (WHVP-FHVP) (from 23-9 (3 4) to 21 8 (3 4) mmHg: p<0005) occurred 60 minutes after Is-5-Mn due entirely to a fall in WHVP, associated with decreased estimated liver blood flow (from 1940 (159) to 1639 (179) ml/min: p<0O05). Right atrial and pulmonary artery pressures and cardiac index fell significantly whilst mean arterial pressure remained unaffected. Heart rate and the calculated systemic vascular resistance index increased significantly. Significant correlations existed between the reduction in portal pressure gradient and fall in cardiac index (r=0-65, p<005) and increase in systemic vascular resistance index (r=0-72, p<002). The observed decrease in estimated liver blood flow, in association with an increase in systemic vascular resistance index, suggests that baroreceptor mediated splanchnic vasoconstriction may be one of the factors responsible for the fall in portal pressure, rather than portal venous dilatation.
SUMMARY Nitrates have been shown to decrease portal pressure in cirrhotic patients with portal hypertension and this has been attributed to decreased portal venous resistance. We studied the effect and mechanism of action of oral administration of isosorbide-5-mononitrate (Is-5-Mn) (20 mg), which, unlike the dinitrate, does not require hepatic biotransformation to a vasoactive metabolite on portal and systemic haemodynamics in 11 patients with portal hypertension complicating cirrhosis. A significant reduction in portal pressure gradient (WHVP-FHVP) (from 23-9 (3 4) The patients were examined after an overnight The portal fast. A Swann-Ganz pulmonary flotation catheter from the WH and an hepatic venous balloon catheter were inserted vascular resist through the right subclavian and femoral veins respectively. Estimated liver blood flow (ELBF) was HVR measured by the indocyanine green constant infusion method" before and 60 minutes after the oral administration of 20 mg of Is-5-Mn.
STATISTICAL
The baseline haemodynamic parameters meagured Analysis of tl were: heart rate (bt/min) (electrocardiographically); and after Is-5-right atrial, pulmonary artery and pulmonary capil-Student's t-te lary wedge pressures (mmHg) (RAP, PAP, and were made b PCWP respectively); wedged and free hepatic expressed as n venous pressures (mmHg) (WHVP and FHVP); cardiac output (1/min) ( after administration of the drug whilst no change was seen in hepatic vascular resistance. A reduction in portal pressure gradient was seen in 8 of the 11 patients with a mean overall fall of 2 09 (0.56) mmHg. Changes in systemic haemodynamics were seen by 30 minutes with significant reductions in RAP, PAP, PCWP associated with a significant increase in heart rate. The decrease in cardiac index was only shown 60 minutes after administration of the drug as was the increase in systemic vascular resistance index. No change in mean arterial blood pressure was shown at any time during the study.
The fall in portal pressure correlated with the rise in SVRI (r=0-72; p<0-02) and weakly with the fall in CI (r=0-65; p<0-05) but not between changes in portal pressure gradient and PCWP or RAP. Similarly no correlation was seen between PPG and ELBF.
Discussion
This study confirms that the oral administration of Is-5-Mn (20 mg), the standard single dose used in cardiological practice, is effective (p<O-()05) in reducing portal pressure. The fall in portal pressure gradient was accompanied by, and correlated with, a reduction in the cardiac index and rise in SVRI. The predominant systemic haemodynamic changes produced by the drug were reductions in cardiac preload -that is PCWP, PAP, and RAP, whilst no change l-at the expense of a reduction in arterial pressure. An increase in SVRI was not seen using this larger intravenous dosage.
This dose dependent effect of the nitrates may be responsible for the differences in published studies."613 Although small and large doses appear capable of reducing portal pressure the mechanism whereby it takes place differs, the smaller dose affecting primarily cardiac preload, with a secondary rise in SVRI, whilst larger doses directly affect the arterial circulation, reducing portal pressure by lowering systemic and hence splanchnic perfusion pressure.
The high percentage of responders with respect to a reduction in portal pressure suggests that Is-5-Mn may deserve further assessment as a possible therapeutic agent alone or in combination withtother 'active agents', although it is important to stress that there is continued controversy as to whether a fall in portal pressure results in a decreased risk of variceal bleeding. Furthermore, any proposed long term use of nitrates for the management of portal hypertension should be tempered by the well documented development of tolerance found in cardiological practice. '4 
